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ABSTRACT Inbred mice exhibit strain-specific variation in susceptibility to atherosclerosis and dyslipidemia that
renders them useful in dissecting the genetic architecture of these complex diseases. Traditional quantitative trait
locus (QTL) mapping studies using inbred strains often identify large genomic regions, containing many genes,
due to limited recombination and/or sample size. This hampers candidate gene identification and translation of
these results into possible risk factors and therapeutic targets. An alternative approach is the use of multiparental
outbred lines for genetic mapping, such as the Diversity Outbred (DO) mouse panel, which can be more
informative than traditional two-parent crosses and can aid in the identification of causal genes and variants
associated with QTL. We fed 292 female DO mice either a high-fat, cholesterol-containing (HFCA) diet, to
induce atherosclerosis, or a low-fat, high-protein diet for 18 wk andmeasured plasma lipid levels before and after
diet treatment. We measured markers of atherosclerosis in the mice fed the HFCA diet. The mice were
genotyped on a medium-density single-nucleotide polymorphism array and founder haplotypes were
reconstructed using a hidden Markov model. The reconstructed haplotypes were then used to perform linkage
mapping of atherosclerotic lesion size as well as plasma total cholesterol, triglycerides, insulin, and glucose.
Among our highly significant QTL we detected a ~100 kb QTL interval for atherosclerosis on Chromosome 6, as
well as a 1.4 Mb QTL interval on Chromosome 9 for triglyceride levels at baseline and a coincident 22.2 MbQTL
interval on Chromosome 9 for total cholesterol after dietary treatment. One candidate gene within the
Chromosome 6 peak region associated with atherosclerosis is Apobec1, the apolipoprotein B (ApoB) mRNA-
editing enzyme, which plays a role in the regulation of ApoB, a critical component of low-density lipoprotein, by
editing ApoB mRNA. This study demonstrates the value of the DO population to improve mapping resolution and
to aid in the identification of potential therapeutic targets for cardiovascular disease. Using a DOmouse population
















Identifying novel gene(s) and pathways that regulate susceptibility to
atherosclerosis and its underlying risk factors is critically important for
biomedical science. Genome-wide association studies (GWAS) have
aided in the identification of more than 50 genomic loci associated
with atherosclerosis (Holdt and Teupser 2013) and plasma lipid levels
(Johansen et al. 2011; Swerdlow et al. 2012). However, elucidation of
the mechanisms underlying novel loci resulting from GWAS studies is
challenging, and in most cases such loci only explain a fraction of the
genetic variance related to the trait (Hardy and Singleton 2009; Lucas
et al. 2012; Musameh et al. 2014). For example, GWAS have been
successfully used to identify more than 40 loci for coronary artery
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disease, but these loci in aggregate explain less than 10% of the phe-
notypic variance associated with coronary artery disease (Sayols-
Baixeras et al. 2014).
Mouse models are well suited for studies of complex traits such as
atherosclerosis because environmental conditions and other con-
founding cofactors can be carefully controlled. This reduces the effects
of environmental variation on clinical traits and thus increases the
portion of the variance that can be explained by genetics. Recently,
a “Multiparent Advanced Generation Inter-Cross” (i.e., MAGIC) pop-
ulation was developed from eight inbred strains of mice and is referred
to as the Diversity Outbred (DO) mouse population (Churchill et al.
2012). The DO mice are mosaics of C57BL6/J, A/J, NOD/ShiLtJ,
NZO/HiLtJ, WSB/EiJ, CAST/EiJ, PWK/PhJ, and 129S1/SvImJ, and
these mice complement another large endeavor called the Collabora-
tive Cross (Aylor et al. 2011). Both the DO and Collaborative Cross
populations have tremendous genetic diversity, containing approxi-
mately 45 million segregating single-nucleotide polymorphisms (SNPs)
(Yang et al. 2011). The DO population is maintained by a randomized
outbreeding strategy and thus is an ideal resource for high-resolution
genetic mapping due to the high allelic diversity and increased number
of recombinations represented by this population compared with typical
inbred mouse strains (Svenson et al. 2012).
In the current study, we use DO mice to study plasma lipids and
atherosclerosis. We identify a significant quantitative trail locus (QTL)
for atherosclerosis with a submegabase resolution within a locus pre-
viously identified as associated with atherosclerosis in mice. Using
publically available expression data and expression quantitative
trait loci (eQTL) analysis, we identify Apobec1 as a high-probability
candidate gene. We confirm the eQTL for Apobec1 in the current
study using quantitative real-time polymerase chain reaction and
quantitate possible coregulation of circulating apolipoprotein B (ApoB)
protein levels at this locus.
MATERIALS AND METHODS
Animals and diets
Female DO mice (n = 292; J:DO, JAX stock number 009376) were
obtained from the Jackson Laboratory (Bar Harbor, ME) as 146 full
sibling pairs at 4 wk of age and at outbreeding generation 11 (G11)
(received September 2012). The mice were group housed (n = 5 mice
per cage) with nonirradiated pine bedding and provided with high-
efficiency particulate air-filtered air and free access to sterile water in
a climate-controlled facility under a 12-hr light/dark cycle. Mice were
maintained on a defined synthetic diet, AIN-76A, until 6 wk of age to
control for differences due to variable components of standard chow
(D10001, Research Diets, New Brunswick, NJ); subsequently, 146
mice were transferred to a synthetic high-fat, cholic acid (HFCA) diet
that contained 20% fat, 1.25% cholesterol, and 0.5% cholic acid, to
induce atherosclerotic lesions, and146 mice were maintained on
a high-protein diet that contained 5% fat and 20.3% protein, which
is not atherogenic (D12109C and D12083101, respectively; Research
Diets, New Brunswick, NJ). One sibling from each of the 146 sibling
pairs was randomly assigned to each one of the diets, Figure 1. The
composition of all diets is listed in Supporting Information, Table S1.
The source of fat from the diets varied between the baseline diet (corn
oil) fed to the mice from 4 to 6 wk of age and the dietary treatment
groups (soybean oil plus cocoa butter) fed to the mice from 6 to 24 wk
of age. All mice were maintained on their respective diets until 24 wk
of age, for a total of 18 wk. All procedures were approved by the
IACUC at University of North Carolina (UNC) Chapel Hill (IACUC
Protocol Number 11-299).
Plasma clinical chemistries
To ensure that there were no spurious effects due to the potential
variable composition of standard laboratory chow, these mice were
maintained on a defined synthetic diet for 2 wk (from 4 to 6 wk of age).
At 6 wk of age, the mice were anesthetized using isoflurane and blood
was collected after 4 hr of fasting into ethylenediaminetetraacetic
acid2containing microtubes from the retro-orbital sinus. This was re-
peated at 24 wk of age, after 18 wk of dietary treatment. Blood samples
were centrifuged for 10 min at 9,000 rcf at 4 and stored at 280. The
plasma levels of total cholesterol, glucose, and triglycerides were quanti-
tated using a Biolis 24i Analyzer (Carolina Liquid Chemistries, Winston-
Salem, NC). Insulin was determined using the Alpco Mouse Ultrasensitive
Insulin ELISA assay (Alpco Inc, Salem, NH); samples and controls were
run in duplicate and optical densities were measured at 450 nm using
a microplate reader and analyzed with Gen5 Data Analysis Software
(Bio-Tek, Winooski, VT). Data are presented as mean 6 SD and
significance was determined using a Student’s t-test.
Figure 1 Overall design of the QTL mapping
study. Mice obtained from the Jackson Lab-
oratory were fed a chow diet of variable
composition before arriving at the University
of North Carolina Mouse Facilities at 4 wk of
age. Mice were transferred to a controlled
synthetic diet from 4 to 6 wk of age (AIN-76A).
At 6 wk of age, clinical markers of cardiovascu-
lar disease were measured, and baseline QTL
mapping was performed. The mice were then
transferred to one of two diet groups such that
one sibling of each sib pair was randomly
assigned to either the high-fat, cholic acid diet
group designed to induce atherosclerosis or
the high-protein diet group, expected to be
nonatherogenic. QTL mapping was then per-
formed in 24-wk-old mice after diet exposure.
Quantification of atherosclerotic lesions was
performed in the mice at 24 wk of age. QTL,
quantitative trait locus.
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Atherosclerotic lesion size
Hearts, including the proximal aorta, were carefully dissected from
24-wk-old mice, perfused with 1X phosphate-buffered saline, and
stored in 10% formalin at 4. A transverse cut, parallel to the atria, was
made to remove the top portion of the hearts, which were then em-
bedded in Optimal Cutting Temperature compound and stored at
280. Serial sections (10 mm thick) from the aortic sinus were
mounted onto slides. Cross sections were arranged eight to a slide
and approximately 10214 total slides were obtained from each mouse
heart, for a total of 802112 cross sections through 4002560 mm of
the aortic sinus per animal. Sections were stained with Oil Red O to
measure lipid accumulation. To summarize, slides were fixed with
formalin for 15 min, rinsed with water then 60% isopropanol, stained
for 1 hr in freshly prepared Oil Red O solution, and rinsed with 60%
isopropanol then water. Once stained, the slides were imaged using
a Zeiss AxioCam MR3 (Zeiss, Munich, Germany), and atherosclerotic
lesion area was quantified using Image J software (http://imagej.nih.
gov/ij). Data are presented as the average lesion area in mm2.
Apobec1 mRNA isoform expression
Quantitative polymerase chain reaction was performed in triplicate using
a High-Capacity Reverse Transcriptase Kit (Applied Biosystems, Foster
City, CA). Following cDNA conversion, 1 mL of sample cDNA, 2 mL of
KAPA Sybr Fast qPCR mastermix (KK4610), and 0.5 mM primers were
added to each well of a 384-well plate. Apobec1 primers were custom-
designed and ordered from Eurofins MWG Operon (Huntsville, AL).
The long transcript was amplified using the following primer set
59-cagcggtgtgactatccaga-39 (left primer) and 59-ttggccaataagcttcgttt-39
(right primer). This primer set was designed to recognize the known
Apobec1 transcript Apobec1-001 (ENSMUST00000112586.1). The short
transcript was amplified using the following primer set 59-cccatgagcgttg
gattc-39 (left primer) and 59-tcaaccacgggcagtctt-39 (right primer). This
primer set was designed to recognize the known Apobec1 transcript
Apobec1-004 (ENSMUST00000143356.1). A serial dilution of pooled
samples was used to create a standard curve. Sterile water was used as
a negative control.
Quantification of ApoB in the DO mice
ApoB protein levels were measured using the mouse Apolipoprotein B
Sandwich-ELISA method in 96-well format using the ApoB ELISA kit
from Elabscience (Wuhan, China) in duplicate following the manu-
facturer’s instructions. Optical densities were measured at 450 nm
using a microplate reader and analyzed with Gen5 Data Analysis
Software (Bio-Tek, Winooski, VT).
Differential expression of genes in peak regions
Data were obtained from The Jackson Laboratory Gene Expression
Strain Survey and used for the analysis of differential expression of
candidate genes from liver tissue of female C57BL6/J, A/J, NOD/ShiLtJ,
NZO/HiLtJ, WSB/EiJ, CAST/EiJ, PWK/PhJ, and 129S1/SvImJ mice
(http://cgd.jax.org/gem/strainsurvey26/v1). Mice were maintained for
11 wk on standard chow diet (4% fat content). Genes were identified
as differentially expressed between the DO founder strains using anal-
ysis of variance and significant between strains differences were calcu-
lated using Tukey’s Post Hoc test. We used a Bonferroni correction to
determine statistical significance and correct for multiple comparisons.
Genotyping
DNA was extracted and purified from tail biopsies taken from 6-wk-
old mice using QIAGEN DNeasy kit according to the manufacturer’s
instructions. Genotyping was performed using the Mega Mouse Uni-
versal Genotyping Array (MegaMUGA) by GeneSeek (Neogen, Lansing,
MI) (Welsh et al. 2012). The MegaMUGA array is built on the Illumina
Infinium platform and contains 77,800 SNP markers that are distributed
throughout the genome at an average spacing of 33 kb. For the mapping,
genomes were reconstructed based on the X and Y allele intensities from
the array and founder haplotypes were reconstructed using a hidden
Markov model. The reconstructed haplotypes were then used to perform
linkage mapping.
QTL mapping
QTL mapping was performed using the R package DOQTL, version
0.99. To summarize, DOQTL reconstructs the genome in terms of
founder haplotypes and performs QTL mapping by regressing the
phenotypes on the founder haplotypes with an adjustment for kinship
between the mice. Diet was included as an additive covariate for postdiet
measurements, except lesion size, which was performed using only the
subset of mice fed the HFCA diet (n = 146). Candidate genes were
identified by position based on the Wellcome Trust Sanger mouse
genomes database, www.sanger.ac.uk, release 1303, based on genome as-
sembly GRCm38 (Yalcin et al. 2011). QTL support intervals were defined
by the 95% Bayesian credible interval, calculated by normalizing the area
under the QTL curve on a given chromosome (Sen and Churchill 2001).
The mapping statistic reported is log of the odds ratio (LOD). The
significance thresholds were determined by performing 1000 permu-
tations of genome-wide scans by shuffling phenotypic data in relation
to individual genotypes. Significant QTL were determined at a genome-
wide P-value of,0.05 and suggestive QTL were determined at a P-value
of ,0.63. The latter corresponds to one false positive per genome scan
(Lander and Kruglyak 1995).
RESULTS
Effects of diet on clinical markers of cardiovascular
disease in DO mice
Our studies using the DO mice were designed to examine nutrigenetic
or gene · diet interactions and the overall design is outlined in Figure 1.
Thus, we used several diets that we outline here. First, to standardize our
measurements for this study and our planned future studies, all of the
DO mice were placed on a synthetic, chemically-defined diet (AIN-76)
upon arrival at the University of North Carolina, Chapel Hill. This diet
is henceforth referred to as the baseline diet and was administered for
2 wk. After 2 wk of this defined diet, all 292 DO mice were phenotyped
for a variety of clinical traits associated with cardiovascular disease risk.
These data were used for QTL mapping. At the end of the 2-wk baseline
diet, one mouse from each sibling pair was assigned to one of two diets
for subsequent investigation of gene · diet interactions. These diets also
were synthetic and chemically defined and included an HFCA diet
designed to induce atherosclerosis and a low-fat, high-protein diet not
expected to be atherogenic. The DO mice were fed these diets for 18 wk
and then phenotyped at 24 wk of age.
There was considerable variation among the mice in the clinical
traits measured while the mice were on the baseline diet (Table 1).
After we administered the diets, we found there was a robust and statis-
tically significant increase in plasma cholesterol in response to the HFCA
diet (199.9 6 68.6 mg/dL) compared with both the high-protein diet
(91.76 25.1 mg/dL) and baseline levels (97.66 31.5 mg/dL) (Figure S1
and Table 1). Conversely, triglyceride levels decreased in response to the
HFCA diet (32.3 6 12.2 mg/dL) compared with both baseline levels
(59.3 6 26.7 mg/dl, P , 0.05) and in mice on the high-protein diet
(57.7 6 30.8 mg/dL, P , 0.05), (Figure S1 and Table 1).
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Identifying QTL for clinical markers of cardiovascular
disease in DO mice at baseline
We performed QTL mapping for several clinical markers of cardiovas-
cular disease in 6-wk-old mice fed the baseline (AIN-76) diet. Sig-
nificant QTL were determined at a genome-wide P-value of ,0.05 and
the QTL support interval was defined using the 95% Bayesian credible
interval (Table 2). We identified a highly significant QTL for triglycer-
ides on Chromosome 9 with a peak SNP located at 51.4 Mb (LOD =
11.3; n = 262 mice) (Figure 2A). DO mice carrying the CAST/EiJ allele
at the Chromosome 9 QTL have greater triglyceride levels (Figure 3A).
There are 34 candidate genes within the QTL interval on Chromosome
9 (Figure 3B). We identified suggestive QTL for total cholesterol at
baseline on Chromosome 13 with a peak SNP located at 30.4 Mb
(LOD = 6.5; n= 277 mice) (Figure 2B) and for glucose at baseline on
Chromosomes 5 and 7 with peak SNPs located at 92.6 Mb on Chro-
mosome 5 (LOD = 7.0; n = 257 mice) and 27.2 Mb on Chromosome 7
(LOD = 6.5; n = 257 mice) (Figure 2C).
Identifying QTL for clinical markers of cardiovascular
disease in the DO after dietary treatment
To assess the effects of diet in the DO, we determined the genetic
architecture of several markers of cardiovascular disease by quantifying
these phenotypes at 24 wk of age after dietary treatment. Because diet
had significant effects on the phenotypes, it was included in the
mapping model as an additive covariate. We observed a significant QTL
for plasma cholesterol on Chromosome 9 with a peak LOD score of
7.54 at 48.3 Mb (47.84270.04 Mb) (Figure 4A and Table 2). The CAST/
EiJ founder haplotype was associated with high levels of cholesterol
based on the founder allele contribution in the region (Figure 4B). This
is a relatively large QTL interval of 22.2 Mb based on the Bayesian
credible interval (P = 0.95) and the entire interval contains 391 known
and predicted genes. The peak SNP is within 3 Mb of the peak SNP
identified by mapping of baseline triglyceride levels in this population of
mice, suggesting that this genes at this locus are critical in the overall
regulation of lipid metabolism.
Differential expression of candidate genes in DO
founder strain mice
To prioritize candidate genes within the QTL intervals we identified,
we analyzed hepatic gene expression among the founder strains for
the 34 genes in the region from a publically available dataset (http://
cgd.jax.org/gem/strainsurvey26). We first identified genes whose ex-
pression varies across the progenitor strains using 1-way analysis of
variance analysis and using a Bonferroni correction based on the
number of probes tested (0.05/68 probes representing the 34 genes
in the locus). Based on this analysis, we identified 10 probes repre-
senting 9 genes that are differentially expressed: 1110032A03Rik,
1810046K07Rik, Alg9, Bco2, Cryab, Gm684, Ppp2r1b, Pts, and Sik2
(Figure S2, A2I).
The DOQTL package identifies the contribution of the founder
alleles to the QTL. For the Chromosome 9 triglyceride QTL, we observed
that allelic contribution from the CAST/EiJ founder at this locus is
associated with greater triglyceride levels, whereas comparatively low
triglyceride levels are associated with allelic contribution from the other
seven founder strains (Figure 3A). Thus, we next performed pair-wise
comparisons using Tukey’s HSD for the nine differentially expressed
n Table 1 Effects of high-protein, high-fat, cholic acid diets on cardiovascular risk factors in the DO mice
Baseline (AIN-76A) High Protein High-Fat, Cholic Acid
n Mean n Mean n Mean
Cholesterol, mg/dL 277 91.7 6 25.1 128 97.6 6 31.5 136 199.9 6 68.6,
Triglycerides, mg/dL 262 59.5 6 26.5 128 57.7 6 30.8 136 32.3 6 12.1,
Glucose, mg/dL 257 155.2 6 43.8 130 190.5 6 49.9 137 177.9 6 45.1
Insulin, ng/mL 235 0.8 6 0.4 129 1.7 6 1.1 133 1.4 6 0.7
The values shown are means 6 SD. Plasma clinical chemistries were measured at baseline (in 6-wk-old mice), after 2 wk on the synthetic-defined diet AIN-76A and
with 4 hr fasting. Mice were transferred to one of two diets, either a high-fat, cholic acid diet or a low-fat, high protein diet, and maintained on these diets for 18 wk.
Plasma clinical chemistries were measured again (in 24-wk-old mice) after diet treatment and with 4 hr fasting. Significant differences between the baseline diet
measures and either diet treatment group (, where P, 0.05) or significant differences between the two different diets after 18 weeks of diet treatment (, where P,
0.05) are indicated.
n Table 2 QTL for cardiovascular risk factors in the DO mice at baseline and after dietary treatment










Triglycerides 9 11.3 51.4 (50.2251.6) Yes Trigq1 (40270) ApoA5 Suto and Sekikawa 2003
Total
cholesterol
13 6.5 30.4 (28.7243.8) No Hmgcs1 (202100) Hmgcr Welch 1996
Glucose 5 7.0 92.6 (86.3299.0) No Bglu13 (842110) Hnf1a, Pdx1 Zhang et al. 2012
Insulin 19 5.4 58.6 (22.6260.8) No Tanidd1 (36261) Not Determined Kim 2001
After diet
Triglycerides 12 5.8 97.6 (49.62102.3) No Tglq2 (55289) ApoB Srivastava 2006
Total
cholesterol
9 7.5 48.3 (47.8270.0) Yes Cq4 (15-50 Mb),
Cq5 (32266)
ApoA4 Suto and Sekikawa 2003
Glucose 12 5.7 70.9 (26.7275.1) No Bglu15 (10242) Adam17 Zhang et al. 2012
Insulin 13 7.0 8.7 (5.7210.4) No NA NA NA
Clinical markers of cardiovascular disease were measured in study animals after 4 hr of fasting at both 6 and 24 wk of age. Baseline measures are from 6-wk-old fasted
mice fed a synthetic diet. Measures at 24 wk of age, after diet, include mice on both the low-fat, high protein diet and the high-fat, cholic acid diet; diet was used as
a covariate in the analysis. The statistic reported is log of the odds ratio (LOD). QTL, quantitative trait loci; DO, Diversity Outbred; NA, not available.
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genes to identify genes that are differentially expressed in CAST/EiJ
compared with the other founder strains and thus match the overall
allelic effects at the QTL. Of the nine genes differentially expressed,
Bco2 and Ppp2r1b most closely match the allele effects of the QTL and
are differentially expressed between CAST/EiJ and the other progenitor
strains, Figure S2, A2B. We note that the locus we identified is adjacent
to a region harboring genes known to influence plasma lipid levels, in-
cluding Apoa1, Apoa4, Apoa5, and Nnmt. Both Apoa4 and Nnmt are
differentially expressed among the strains, but only Nnmt is differentially
expressed in CAST/EiJ mice (Figure S3).
Identification of Apobec1 as a candidate for regulating
lesion size in DO mice
Atherosclerosis is a complex trait and studies using mice have
identified numerous QTL for this trait (Wang et al. 2005); but this
trait has not yet been evaluated in the DO mice. Based on previous
studies, a HFCA diet can induce formation of atherosclerotic lesions
(Paigen et al. 1987). Indeed, we found that none of the mice fed the
high-protein diet exhibited any lesions, and our subsequent analyses
focus only on the subset of DO mice that were fed the HFCA diet.
We found that 76% of the DO mice were susceptible to ath-
erosclerosis with lesions induced by the HFCA diet, with a range in
lesion size from 38 to 33,200 mm2. Based on this highly variable
phenotype, we were able to identify a highly significant QTL on Chro-
mosome 6 (LOD = 10.7; 122.62122.7 Mb) (Figure 5A). Although our
Chromosome 6 peak SNP, UNC11996440, is within the 95% confidence
interval of a previously reported QTL, Ath37, the interval is refined to
sub-Mb resolution using the DO. The 95% confidence interval reported
for this previously defined QTL encompasses an 11.8-Mb interval,
whereas our Chromosome 6 atherosclerosis peak maps to a refined
100,000-kb region containing six genes (Figure 5C). One candidate gene
within the Chromosome 6 peak region is Apobec1, the apolipoprotein B
mRNA-editing enzyme, which plays a role in the regulation of ApoB,
a critical component of LDL, by editing ApoB mRNA to produce the
short ApoB48 isoform. Misregulation of Apobec1 results in altered ApoB
isoform editing. For example, Apobec12/2 mice have greater levels of
ApoB100 compared with the edited isoform, ApoB48 (Nakamuta et al.
1996) and transgenic rescue of Apobec1in Apobec12/2 animals has been
shown to directly alter chylomicron production (Blanc et al. 2012).
Apobec1 is an attractive candidate gene for influencing diet-induced
lesion size based on the known function of Apobec1 in lipid homeostasis
and a causal allele for Apobec1 has not been previously identified as
associated with atherosclerosis. Additionally, we found that total cho-
lesterol levels after dietary treatment were significantly correlated with
both the short and long isoforms of Apobec1 (r = 0.6 and r = 0.57,
respectively), but not ApoB levels in these mice (r = 0.06).
Figure 2 QTL mapping of clinical markers of cardiovascular disease in 6-wk-old DO mice at baseline. Genome-wide QTL scans for loci affecting
plasma levels of triglycerides (A), total cholesterol (B), and glucose (C) in the DO population at baseline. Chromosomes 1 through X are
represented numerically on the x-axis, and the y-axis represents the LOD score. The relative width of the space allotted for each chromosome
reflects the relative length of each chromosome. Mice were maintained on a synthetic diet for 2 wk and then phenotyped for plasma clinical
chemistries at 6 wk of age. Colored lines show permutation-derived significance thresholds (N = 1000) at P = 0.05 (LOD = 7.57, shown in red), P =
0.10 (LOD = 7.17, shown in orange), and P = 0.63 (LOD = 5.79, shown in yellow). QTL, quantitative trait locus; DO, Diversity Outbred; LOD, log of
the odds ratio.
Figure 3 High-resolution mapping of significant hits on Chromosome 9
for plasma triglyceride levels. The eight coefficients of the QTL model
show the effect of each founder haplotype on the phenotype. The model
coefficients for the mapping of baseline triglycerides are plotted for each
founder allele at each marker along Chromosome 9 and shading identifies
the 95% Bayesian estimated interval around the peak (A). There are 34
potential candidate genes within the Chromosome 9 locus associated
with plasma triglycerides at baseline (B). QTL, quantitative trait locus.
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A/J specifically expresses a long isoform of Apobec1,
which is induced in response to a HFCA diet
We found that DO mice containing the A/J allele at the Chr 6 QTL had
larger aortic lesions (Figure 5B). Among genes in the Chr 6 QTL interval,
only Apobec1 has significant differential hepatic expression in the A/J
strain, which expresses greater levels of Apobec1 (P , 0.0125) (Figure 5,
D2G). Interestingly, strain-specific differences in isoform expression of
Apobec1 were recently identified between A/J and C57BL/6J mice, where
C57BL/6J mice express a truncated Apobec1 protein (Hassan et al. 2013).
More importantly, using AXB and BXA recombinant inbred strains they
demonstrate genetic regulation of mRNA editing by Apobec1, such that
animals expressing the A/J-specific isoform of Apobec1 exhibit greater
editing efficiency of Apobec1 targets compared with C57BL/6J animals.
We quantitated the expression of Apobec1 in liver tissue from A/J
and C57BL/6J mice fed either the HFCA diet or the control synthetic
diet and found that on the synthetic diet A/J expresses more of the
long isoform of Apobec1 compared with C57BL/6J (Figure 6B),
whereas A/J and C57BL/6J express similar levels of the short isoform
of Apobec1 while on a synthetic diet (Figure 6A). In response to the
HFCA diet, expression of both isoforms of Apobec1 is significantly
increased in both A/J and C57BL/6J mice compared with Apobec1
levels in the mice on the synthetic diet (P . 0.05). The short isoform
of Apobec1 is induced 2.5-fold in C57BL/6J animals and 3.5-fold in A/J
animals in response to the HFCA diet. The long Apobec1 isoform is
induced 2.5-fold in C57BL/6J animals and fourfold in A/J animals.
cis-eQTL for Apobec1 exhibit isoform-specific allele
effects patterns in the DO mice
Based on the differences in expression of Apobec1 between A/J and
C57BL/6J mice, we hypothesized that the expression of Apobec1 may
be genetically regulated. Thus, we surveyed two publically available
databases for expression QTL data to determine whether a natural
variant near the Apobec1 gene affects its expression. Specifically, we
queried a panel of inbred strains of mice called the hybrid mouse
diversity panel and The Jackson Laboratory’s Diversity Outbred eQTL
viewer, data located at http://systems.genetics.ucla.edu/data/hmdp and
http://cgd.jax.org/apps/eqtlviewer-beta/, respectively (Ghazalpour et al.
2012). Apobec1 expression varied significantly among the hybrid mouse
diversity panel strains and the major locus regulating expression map-
ped directly over the Apobec1 gene, at 122 Mb on Chromosome 6 (data
not shown). Similarly, the Jackson Laboratory’s DO eQTL viewer iden-
tifies a cis-eQTL associated with Apobec1 expression (Figure S4A). Sim-
ilar to our results, these data demonstrate that the A/J allele is associated
with greater expression of Apobec1 (Figure S4B).
Considering our observations of the effect of genetic background on
Apobec1 expression in liver tissue and recent observations that mouse
genetic background regulates isoform usage in macrophages, we next
asked whether there was a difference in the genetic regulation of each
of these isoforms among the DO founder strains. We performed QTL
mapping of mRNA expression levels of either the short or long isoform of
Apobec1 from RNA isolated from liver tissue from the present DO mouse
study population. We identified highly significant cis-eQTL for both iso-
forms on Chromosome 6 with the peak SNP located at 121.8 Mb with
a maximum LOD score of 9.9 associated with expression of the short
isoform (P, 0.05, n = 252 mice) and at 123.4 Mb with a maximum LOD
score of 15.7 associated with expression of the long isoform (P, 0.05, n =
251 mice) (Figure 7, A and B), respectively. When we estimate the effect of
each founder at each marker along Chromosome 6, we see that CAST/EiJ
alleles are associated with greater expression of the short isoform (Figure
7C), whereas A/J alleles are associated with greater expression of the long
isoform (Figure 7D). We also mapped the ratio of Apobec1 isoforms and
observe a highly significant cis-eQTL with a max LOD score of 41.0 at
122.6 Mb (P , 0.05, n = 251 mice) (Figure 7, E and F).
Apobec1 and ApoB levels are dependent on the
genotype of UNC11996440, the Chromosome 6 peak
SNP associated with atherosclerosis
Based on the association of the A/J founder with atherosclerotic lesion
size, we hypothesized that a causal allele located in the Apobec1 sequence
would be private to A/J. However, there are no documented SNPs that
are private to A/J within the refined peak region of 122.62122.7 Mb on
Chromosome 6. The peak SNP for this locus, UNC11996440, is located
Figure 4 Effect of diet on total cholesterol in the DO mice. Genome-wide QTL scan for loci affecting plasma levels of total cholesterol after 18 wk
of dietary treatment (A). Chromosomes 1 through X are represented numerically on the x-axis, and the y-axis represents the LOD score. The
relative width of the space allotted for each chromosome reflects the relative length of each chromosome. Plasma was taken from 24-wk-old mice
after 18 wk of dietary treatment. Colored lines show permutation-derived significance thresholds (N = 1000) at P = 0.05 (LOD = 7.57, shown in
red), P = 0.10 (LOD = 7.17, shown in orange), and P = 0.63 (LOD = 5.79, shown in yellow). The eight coefficients of the QTL model show the effect
of each founder haplotype on the phenotype. Shading identifies the 95% Bayesian credible interval around the peak (B). DO, Diversity Outbred;
QTL, quantitative trait locus; LOD, log of the odds ratio.
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distal to the Apobec1 gene on Chromosome 6 at 122.67 Mb, whereas
Apobec1 lies between 122.5 and 122.6 Mb. In addition to the cis-eQTL
data for Apobec1 expression, this finding suggests that a distant SNP
affecting Apobec1 expression may be responsible for the association
between the A/J haplotype and atherosclerotic lesion size. However, if
the association of the A/J haplotype with increased lesion size in the DO
mice is mechanistically related to Apobec1 expression, then we would
expect Apobec1 expression levels to differ based on the genotype of
UNC11996440. We identified T as the major allele (frequency = 0.69)
and C as the minor allele (frequency = 0.31) at the tagging SNP
UNC11996440. The genotype at this SNP significantly affects Apobec1
mRNA expression levels (P . 0.001) (Figure 8A). We next hypothe-
sized that the association at this locus may be mechanistically related to
the role of Apobec1 in editing its primary target, ApoB, as elevated
plasma ApoB is a known risk factor for atherosclerosis. Therefore, we
quantified plasma ApoB levels in duplicate using two mouse-specific
ApoB Sandwich-ELISA plates (N = 80 mice). Plasma samples from only
the HFCA diet-fed mice were used and samples were chosen to repre-
sent a range of atherosclerotic lesion sizes. As shown in Figure 8B, ApoB
levels are significantly different between the genotype groups at the
tagging SNP UNC11996440 (P . 0.001). Therefore, in addition to
identifying the A/J-specific isoform of Apobec1 as associated with ath-
erosclerotic lesion size in the DO mice, these data suggest that this
association may be attributable to the role of Apobec1 in editing ApoB.
DISCUSSION
The DO was designed to be a high-resolution genetic mapping panel.
The use of DO mice for mapping offers a number of advantages over
classical approaches to mouse genetics, including high mapping res-
olution, increased heterozygosity, and uniformly distributed genetic
Figure 5 QTL mapping of atherosclerosis in the DO mice. Genome-wide QTL scan for loci affecting atherosclerotic lesion size in mice fed a high-fat,
cholic acid diet (A). Chromosomes 1 through X are represented numerically on the x-axis, and the y-axis represents the LOD score. The relative width of
the space allotted for each chromosome reflects the relative length of each chromosome. Hearts were harvested from 146 mice after 18 wk on a high-fat,
cholic acid diet. Colored lines show permutation-derived significance thresholds (N = 1000) at P = 0.05 (LOD = 7.57, shown in red), P = 0.10 (LOD = 7.17,
shown in orange), and P = 0.63 (LOD = 5.79, shown in yellow). The eight coefficients of the QTL model show the effect of each founder haplotype on the
phenotype. A/J founder alleles are associated with larger lesion size in the DOmice (B). There are six candidate genes within the 100,000-kb QTL interval
on Chromosome 6: Apobec1,Gdf3,Dppa3,Nanog, Slc2a3, and the predicted geneGm26168 (C). Gene expression data were obtained from livers from
female C57BL6/J, A/J, NOD/ShiLtJ, NZO/HiLtJ, WSB/EiJ, CAST/EiJ, PWK/PhJ, and 129S1/SvImJ mice (http://cgd.jax.org/gem/strainsurvey26). Of the
six candidate genes in the QTL interval on Chromosome 6, four were assayed by microarray for hepatic gene expression: Apobec1 (D), Gdf3 (E), Dppa3
(F), and Nanog (G). Apobec1 is the only candidate in this region that matches our allele effects such that A/J mice specifically express higher levels of
Apobec1. QTL, quantitative trait locus; DO, Diversity Outbred; LOD, log of the odds ratio.
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variation across the genome (Svenson et al. 2012). Using the newly
developed DO mouse resource, we were able to refine the positions
and identify new candidate genes for previously mapped QTL for
atherosclerosis, a highly complex phenotype associated with human
disease. We further interrogate this QTL by using publically available
data, by quantitating mRNA levels for Apobec1, and by investigating
the protein target of Apobec1 to identify a potential mechanism for
this QTL. We discuss each of these in detail.
Atherosclerosis in the DO
Atherosclerotic lesion development is the most common cause of
cardiovascular disease. Here, we characterize for the first time the
development of diet-induced atherosclerotic lesions in the newly developed
DO mouse population. In the present study, 292 mice on either a HFCA
diet designed to induce atherosclerotic lesions or a nonatherogenic, low-
fat, high-protein diet were phenotyped for atherosclerosis. We found that
none of the mice fed the high-protein diet exhibited any lesions. We
found that 76% of the DO mice were susceptible to lesions induced by
the HFCA diet, with a range in lesion size from 38 to 33,200 mm2. We
detected one locus on Chromosome 6 for atherosclerosis that maps
within the 95% confidence interval of a previously reported QTL,
Ath37 (Ghazalpour et al. 2006), which was identified in studies using
sub-congenic mice between C57BL/6J and CAST/EiJ. The locus in the
current study contains Apobec1, which was originally described as the
enzyme responsible for deamination of a cytosine in mature ApoB
mRNA, resulting in a premature stop codon and production of the
truncated protein ApoB48. Lipoproteins containing ApoB48 are more
efficiently cleared from the circulation as demonstrated by adenoviral
overexpression studies that reduce plasma lipid levels (Teng et al. 1997);
in contrast, Apobec12/2 mice synthesize only ApoB100 and have in-
creased atherosclerosis when crossed to Ldlr2/2 mice (Powell-Braxton
et al. 1998).
Figure 6 A/J preferentially expresses the long isoform
of Apobec1 in response to a high-fat, cholic acid diet.
Apobec1 expression levels of the short (A) and long (B)
isoforms from RNA from liver tissue from A/J and
C57BL/6J founder strain mice. A/J mice on a high-fat,
cholic acid diet exhibit increased expression of both the
long and short transcripts of Apobec1 in a diet-dependent
manner, P . 0.05. Apobec1 levels for each sample were
normalized relative to RPS20. Fold changes are reported as
the relative expression in A/J vs. C57BL/6J samples. Data
are presented as mean6 SD, and significance was deter-
mined using a Student’s t-test.
Figure 7 Cis-eQTL for hepatic Apobec1 short and long isoforms in the DO mice. Genome-wide QTL scan for eQTL regulating expression of the
short (A) and long (B) Apobec1 isoforms in the DO mice. Chromosomes 1 through X are represented numerically on the x-axis, and the y-axis
represents the LOD score. The relative width of the space allotted for each chromosome reflects the relative length of each chromosome. Colored
lines show permutation-derived significance thresholds (N = 1000) at P = 0.05 (LOD = 7.57, shown in red), P = 0.10 (LOD = 7.17, shown in
orange), and P = 0.63 (LOD = 5.79, shown in yellow). The eight coefficients of the QTL model show the effects on the phenotype contributed by
each founder haplotype on Chromosome 6 for mapping of the short (C) and long (D) isoforms of Apobec1. Shading identifies the 95% Bayesian
credible interval around the peak. eQTL, expression quantitative trait loci; DO, Diversity Outbred; LOD, log of the odds ratio.
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Closer examination of the locus we identified here indicates that A/J
mice contain a susceptible allele, which is unexpected as A/J has
classically been defined as an atherosclerosis-resistant mouse strain
(Paigen et al. 1985). However, it is possible that if Apobec1 editing is
affected by an allele carried by the A/J strain, this effect could be
masked by transgressive variation or epistasis in inbred A/J animals.
When we queried the Sanger SNP database for alleles private to A/J
within 10 kb of the Apobec1 gene sequence (122,567,8902122,612,426
Mb), we found that there are no documented SNPs that are private to
A/J. However, the association of distant SNPs influencing gene expres-
sion of genes as far as 300 kb away is not uncommon (Guenther et al.
2014). Although our data suggest that a distant SNP affecting Apobec1
expression may be responsible for the association between the A/J
haplotype and atherosclerotic lesion size, we have not yet ruled out
an association between lesion size and the other five genes in the locus,
nor have we ruled out nearby genes with A/J-specific alleles. Addition-
ally, in our study we did not find lesion size to be correlated with
Apobec1 expression (r = 20.02) although total cholesterol was corre-
lated with this phenotype (r = 0.60).
Recently, Hassan et al. (2013) have reported that genetic differ-
ences between C57BL/6J and A/J at the Apobec1 gene affect global
RNA editing patterns between these strains. Indeed, this study iden-
tified an A/J-specific isoform of Apobec1 in murine macrophages that
increased the editing efficiency of this enzyme for ApoB as well as
other Apobec1 targets (Rosenberg et al. 2011; Hassan et al. 2013).
Thus, differences in Apobec1 structure or expression could affect edit-
ing or perhaps overall levels of ApoB or another of Apobec1’s target
genes. Our initial studies, in a subset of the DO mice used in this
study, indicate that total ApoB levels may be influenced by this locus.
Mapping clinical markers of cardiovascular disease in
the DO
Measures of cholesterol, triglycerides, and glucose are commonly used
markers of cardiovascular disease. Therefore, we were interested in
investigating the genetic architecture of these traits in the DO mice. We
identified highly a significant QTL for triglycerides in mice at baseline.
The significant QTL on Chromosome 9 for baseline triglycerides is 1.4
Mb in size and is coincident with a 30 Mb QTL previously identified
as associated with triglyceride levels in C57BL/6J x KK-Ay/a F2 mice,
Trigq1. Trigq1 maps to 61 Mb on Chromosome 9 with a peak LOD
score of 4.2 at the marker D9Mit163 (Suto and Sekikawa 2003). The
large Trigq1 locus includes multiple gene candidates known to regulate
lipid levels such as the ApoA5-ApoA4-ApoA3-ApoA1 gene cluster and
Lipc. Although the ApoA5-ApoA4-ApoA3-ApoA1 gene cluster is located
at 46.2 Mb, just proximal to the QTL interval we identified here and
Lipc is located 20 Mb distal to our peak region, these genes would seem
to be excluded based on our results. However, at least one of these
genes, ApoA5, has been well characterized as associated with triglyceride
levels, (Charlton-Menys and Durrington 2005). In humans, a mutation
in ApoA5, also called the Delhi gene, is linked to extremely elevated
triglyceride levels and increased risk of cardiovascular disease (Sinha
et al. 2010; Ramakrishnan et al. 2011). Hepatic lipase, encoded by the
Lipc gene, hydrolyzes triglycerides and phospholipids in lipoprotein
particles and is therefore also likely to be functionally associated with
heart disease. We used publically available gene expression data to
prioritize genes whose expression may be genetically regulated. These
analyses are not able to identify candidate genes that have a functional
variant that affects protein function, protein stability, or binding. Fur-
ther study to confirm that one of the genes in the triglyceride QTL
identified in this study is a causal gene remains to be performed.
This region of Chromosome 9 clearly contains multiple genes that
are important for the regulation of cardiovascular disease risk factors.
We also identified the same region as associated with total cholesterol
after dietary treatment in our DO mouse population. Additionally, the
human syntenic region of the Chromosome 9 QTL we identified as
associated with both baseline triglycerides and total cholesterol after
dietary treatment has been identified in several human GWAS studies
as associated with multiple atherosclerosis risk factors across multiple
human populations (Hu et al. 2013; Weissglas-Volkov et al. 2013;
Zhou et al. 2013). When one QTL contains more than one causal
variant, the Bayesian interval calculation may fail to differentiate ge-
netic signals from the closely linked genes. Several studies have sug-
gested the use of 2-LOD support intervals for generating conservative
estimates of genes for candidate testing. Indeed, in our study the 95%
Bayesian credible intervals represent approximately 1-LOD support
intervals for baseline triglycerides and for total cholesterol after diet
Figure 8 Apobec1 and ApoB levels are dependent on the genotype of UNC11996440, the Chromosome 6 peak SNP associated with
atherosclerosis. Genotyping was performed using the Mega Mouse Universal Genotyping Array (MegaMUGA). Apobec1 mRNA levels were
measured by quantitative polymerase chain reaction from liver tissue from the DO mice. Expression levels of the Apobec1 long isoform differed
significantly between genotype classes (P. 0.001) (A). ApoB protein levels were measured in a subset of the mice phenotyped for atherosclerosis
(N= 80 mice) using a mouse Apolipoprotein B Sandwich-ELISA method. ApoB expression levels differed significantly between the genotype
classes (P . 0.001) (B).
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treatment and if we broaden these intervals to 2-LOD support inter-
vals, the ApoA5-ApoA4-ApoA3-ApoA1 gene cluster and Lipc gene falls
within the more conservative interval estimate.
We identified a suggestive QTL for total cholesterol on Chromo-
some 13 with a peak SNP located at 30.4 Mb (LOD = 6.5; n = 277
mice) and for glucose on Chromosome 5 with a peak SNP located at
92.6 Mb (LOD = 7.0; n= 257 mice). These suggestive QTL co-localize
with previously reported QTL. The Chromosome 13 locus associated
with baseline cholesterol levels is just proximal to Lipq2, which was
identified in a backcross between MOLF/EiJ and C57BL/6J mice on
with an Ldlr2/2 mutation (Welch et al. 2001). The suggestive QTL
associated with blood glucose on Chromosome 5 is less than 2 Mb
from the peak SNP reported for the QTL, Bglu13, which was identified
in an F2 intercross cross of mutant C3H/HeJ and C57BL/6J carrying
the ApoE2/2 mutation (Zhang et al. 2012).
In summary, we demonstrate here the use of the DO mice for
high-resolution mapping of traits related to atherosclerosis. We iden-
tify several candidate genes for triglycerides in mice on a synthetically
defined diet. Perhaps the most interesting result is the identification of
an atherosclerosis QTL on Chromosome 6 that is 100 kb in size. This
locus contains the candidate gene Apobec1 which is known to alter
circulating lipoprotein composition, but also has widespread RNA
editing capabilities, perhaps indicating an additional mechanism by
which susceptibility to atherosclerosis is regulated.
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